Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Breast 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 13Lymphoma, Non-Hodgkin 12Lymphoma 12Recurrence 11Multiple Myeloma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Leukemia 9Leukemia, Biphenotypic, Acute 8Ovarian Neoplasms 7Neoplasms 7Lymphoma, Mantle-Cell 7Myeloproliferative Disorders 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell 6Hodgkin Disease 6Hematologic Neoplasms 6Lymphoma, Follicular 5Immunoproliferative Disorders 5Immune System Diseases 5Lymphoproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Lymphatic Diseases 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Mesothelioma 3Lung Neoplasms 3

Interventions

pembrolizumab 5Cisplatin 5Platinum 4Pemetrexed 41,2-diaminocyclohexaneplatinum II citrate 4Nivolumab 3Cyclophosphamide 3fludarabine 2atezolizumab 2Ipilimumab 2Carboplatin 2tremelimumab 1sargramostim 1methoxyamine 1lenvatinib 1cediranib 1anetumab ravtansine 1UV1 vaccine 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Interleukin-2 1Imprint II 1Immunotherapy, Adoptive 1Immunoglobulin G 1Gemcitabine 1Disulfides 1Bevacizumab 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Mesothelioma, Malignant × fludarabine × Clear all
NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡